Holen Sie sich die Stockscreener-App
61.73
1.01%
0.62
Handel nachbörslich:
59.31
-2.42
-3.92%
Schlusskurs vom Vortag:
$61.11
Offen:
$60.89
24-Stunden-Volumen:
2.17M
Relative Volume:
0.81
Marktkapitalisierung:
$11.86B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
22.95
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-3.67%
1M Leistung:
+8.58%
6M Leistung:
+5.23%
1J Leistung:
-10.69%
1-Tages-Spanne:
$60.59
$63.21
1-Wochen-Bereich:
$59.56
$66.28
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
61.73 | 11.74B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin Pharmaceutical EVP Trades $381K In Company Stock - Benzinga
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharm - GuruFocus
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock By Investing.com - Investing.com Australia
Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 6,326 Shares of Stock - MarketBeat
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo - Yahoo Finance
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2025 Earnings Call Transcript - Insider Monkey
BioMarin Reports Mixed Q4 Results with Earnings Miss - Intellectia AI
Sanford C. Bernstein Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $94.00 - MarketBeat
Guggenheim Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Bernstein raises BioMarin stock price target on valuation outlook - Investing.com India
Bernstein raises BioMarin stock price target on valuation outlook By Investing.com - Investing.com South Africa
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential - Yahoo Finance
HC Wainwright Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $55.00 - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $95.00 at Oppenheimer - Defense World
BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell itSan Francisco Business Times - The Business Journals
BioMarin Leans Into BD As Voxzogo Competition Intensifies - Citeline News & Insights
BioMarin Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder - Fierce Pharma
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - TradingView
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Bitget
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $95.00 Price Target at Oppenheimer - MarketBeat
BioMarin to Participate in Four Upcoming Investor Conferences in March - PR Newswire
BioMarin Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Stifel raises BioMarin stock price target to $68 on Fold deal value - Investing.com India
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips - Investing.com Nigeria
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
BioMarin Pharmaceutical Q4 Earnings Call Highlights - Yahoo Finance
BioMarin: Q4 Earnings Snapshot - kare11.com
BMRN: 2025 revenue grew 13% with strong profitability; 2026 set for further growth and pipeline advances - TradingView
BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates - Finviz
BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results, Misses Estimates By $1.04 EPS - MarketBeat
BioMarin Pharmaceutical Posts Q4 Loss - Nasdaq
BioMarin posts mixed Q4 results, shares edge lower By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Q4 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Issued - marketscreener.com
BioMarin posts mixed Q4 results, shares edge lower - Investing.com
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: A 38.69% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
BioMarin earnings loom with estimates falling on Voxzogo worries By Investing.com - Investing.com South Africa
BioMarin earnings loom with estimates falling on Voxzogo worries - Investing.com India
(BMRN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $2.34 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Vanguard Group Inc. - MarketBeat
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biomarin Pharmaceutical Inc-Aktie (BMRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer |
Feb 26 '26 |
Sale |
61.36 |
26,061 |
1,599,103 |
72,453 |
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):